Clinical trial NCT05035212: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
Official title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Lower Respiratory Tract Illness
Keywords: Lower Respiratory Tract Illness
RSV
Vaccine
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2021-09-05
Enrollment: 45000
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults:

* At a dose of 120µg.
* In adults 60 years of age and older.
* The duration of the study for each participant will be up to approximately 24 months.
* The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa.

Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in the United States and Argentina.

Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in Argentina.

Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study.
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in the United States and Canada.


Eligibility criteria: Efficacy Study

Inclusion Criteria:

* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

* Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
* Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
* Male or female participants ≥60 years of age.

  * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  * Female participants must not be of childbearing potential.

Exclusion Criteria:

* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
* Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 3).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

* Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
* Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.
* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Substudy A

Inclusion Criteria:

* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

* Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
* Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
* Male or female participants ≥60 years of age.

  * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  * Female participants must not be of childbearing potential.
* Participants who received RSVpreF in the efficacy study.
* Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration.

Exclusion Criteria:

* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
* Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 103).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study

- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

* Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
* Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy A.

* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
* Participant was confirmed by the sponsor to have previously received the study intervention more than once.

Substudy B

Inclusion Criteria:

* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

* Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
* Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
* Male or female participants ≥60 years of age.

  * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  * Female participants must not be of childbearing potential. 6. Participants who received RSVpreF in the efficacy study.
* Participants who received RSVpreF in the efficacy study.
* Participants who have a Visit 2 serology sample available for testing from the efficacy study and did not meet exclusion criteria through Visit 4 of the efficacy study.

Exclusion Criteria:

* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
* Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 203).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

* Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
* Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy B.

* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
* Participant was confirmed by the sponsor to have previously received the study intervention more than once.
* Participants who completed Vaccination 1 from the efficacy study less than 9 months or greater than 15 months prior to revaccination.

Substudy C

Inclusion Criteria:

* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, when indicated.
* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

* Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
* Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
* Male or female participants ≥60 years of age.
* Participants who received RSVpreF in the efficacy study.
* Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration.

Exclusion Criteria:

* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
* Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 303 or Visit 306).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study

- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

* Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
* Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy C.

* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
* Participant was confirmed by the sponsor to have previously received the study intervention more than once.
* Prior history of any subtype of Guillain-Barré syndrome of any etiology.
* Current or prior participation in Substudy A or Substudy B.
* Participants who completed Vaccination 1 from the efficacy study less than 32 months or greater than 40 months prior to revaccination.

Primary outcomes:
measure: Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV season
timeFrame: From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)
measure: Efficacy Study: Proportion of participants reporting prompted local reactions within 7-days after vaccination
timeFrame: Within 7 days after vaccination
measure: Efficacy Study: Proportion of participants reporting prompted systemic events within 7-days after vaccination
timeFrame: Within 7 days after vaccination
measure: Efficacy Study: Proportion of participants reporting AE within 1-month after vaccination
timeFrame: Within 1 month after vaccination (up to 35 days)
measure: Efficacy Study: Proportion of participants reporting SAE throughout the study
timeFrame: Throughout the study duration (an average of 30 months)
measure: Efficacy Study: Proportion of participants reporting NDCMC throughout the study
timeFrame: Throughout the study duration (an average of 30 months)
measure: SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreF
timeFrame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSA
measure: SSA: Proportion of participants reporting prompted local reactions within 7-days after revaccination
timeFrame: Within 7 days after revaccination
measure: SSA: Proportion of participants reporting prompted systemic events within 7-days after revaccination
timeFrame: Within 7 days after revaccination
measure: SSA: Proportion of participants reporting AE within 1-month after revaccination
timeFrame: Within 1 month after revaccination (up to 35 days)
measure: SSA: Proportion of participants reporting SAE throughout the study
timeFrame: Throughout the study duration (approximately 18 months)
measure: SSA: Proportion of participants reporting NDCMC throughout the study
timeFrame: Throughout the study duration (approximately 18 months)
measure: SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreF
timeFrame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSB
measure: SSB: Proportion of participants reporting prompted local reactions within 7-days after revaccination
timeFrame: Within 7 days after revaccination
measure: SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination
timeFrame: SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination
measure: SSB: Proportion of participants reporting AE within 1-month after revaccination
timeFrame: Within 1 month after revaccination (up to 35 days)
measure: SSB: Proportion of participants reporting SAE throughout the study
timeFrame: Throughout the study duration (approximately 18 months)
measure: SSB: Proportion of participants reporting NDCMC throughout the study
timeFrame: Throughout the study duration (approximately 18 months)
measure: SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 3)
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)
measure: SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 4)
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)
measure: SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 3)
timeFrame: Within 7 days after revaccination
measure: SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 4)
timeFrame: Within 7 days after revaccination
measure: SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 3)
timeFrame: Within 7 days after revaccination
measure: SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 4)
timeFrame: Within 7 days after revaccination
measure: SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 3)
timeFrame: Within 1 month after revaccination (up to 35 days)
measure: SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 4)
timeFrame: Within 1 month after revaccination (up to 35 days)
measure: SSC: Proportion of participants reporting SAE after revaccination (Year 3)
timeFrame: Following revaccination and throughout the study duration (approximately 18 months)
measure: SSC: Proportion of participants reporting SAE after revaccination (Year 4)
timeFrame: Following revaccination and throughout the study duration (approximately 6 months)
measure: SSC: Proportion of participants reporting NDCMC after revaccination (Year 3)
timeFrame: Following revaccination and throughout the study duration (approximately 18 months)
measure: SSC: Proportion of participants reporting NDCMC after revaccination (Year 4)
timeFrame: Following revaccination and throughout the study duration (approximately 6 months)
Secondary outcomes:
measure: Efficacy Study: Number of first episode of RSV-associated severe LRTI (sLRTI-RSV) in the first RSV season
timeFrame: From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)
measure: Efficacy Study: Number of first episode of LRTI-RSV in the second RSV season
timeFrame: During the second RSV season (an average of 6 months)
measure: Efficacy Study: Number of first episode of LRTI-RSV across 2 RSV seasons
timeFrame: From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)
measure: Efficacy Study: Number of first episode of RSV-associated ARI (ARI-RSV) in the first RSV season
timeFrame: From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)
measure: Efficacy Study: Number of first episode of ARI-RSV in the second RSV season
timeFrame: During the second RSV season (an average of 6 months)
measure: Efficacy Study: Number of first episode of ARI-RSV across 2 RSV seasons
timeFrame: From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)
measure: Efficacy Study: Number of first episode of sLRTI-RSV in the second RSV season
timeFrame: During the second RSV season (an average of 6 months)
measure: Efficacy Study: Number of first episode of sLRTI-RSV across 2 RSV seasons
timeFrame: From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)
measure: Efficacy Study: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers
timeFrame: Before vaccination, 1-month after vaccination, before season 2 (approximately 12 months after vaccination)
measure: SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSA.
timeFrame: Before revaccination and 1, 6, 12 and 18-months after revaccination with placebo in SSA
measure: SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSA.
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSA
measure: SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSB
timeFrame: Before revaccination and 1, 6, 12 and 18-months after revaccination with placebo in SSB
measure: SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSB.
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSB
measure: SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSC.
timeFrame: Participants receiving placebo at the Year 3 and Year 4 vaccination: 1 month and 3, 3.5, 4 and 4.5 years after efficacy study vaccination. Participants receiving placebo at the Year 3 vaccination: 1 month, 3 and 3.5 years after efficacy study vaccination
measure: SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 3)
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and before revaccination, and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSC
measure: SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 4)
timeFrame: 1 month after receiving the initial vaccination in the efficacy study and before revaccination, and 1 and 6-months after revaccination with RSVpreF in SSC
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: St. Vincent's Birmingham (Pharmacy)
state: Alabama
city: Birmingham
country: United States
facility: St. Vincent's Birmingham
state: Alabama
city: Huntsville
country: United States
facility: Medical Affiliated Research Center
state: Alabama
city: Huntsville
country: United States
facility: Medical Affiliated Research Center
state: Alabama
city: Glendale
country: United States
facility: Lenzmeier Family Medicine/CCT Research
state: Arizona
city: Phoenix
country: United States
facility: Phoenix Clinical LLC
state: Arizona
city: Phoenix
country: United States
facility: HOPE Research Institute
state: Arizona
city: Phoenix
country: United States
facility: The Pain Center of Arizona
state: Arizona
city: Phoenix
country: United States
facility: HOPE Research Institute
state: Arizona
city: Phoenix
country: United States
facility: Cognitive Clinical Trials, LLC
state: Arizona
city: Scottsdale
country: United States
facility: Headlands Research - Scottsdale
state: Arizona
city: Tempe
country: United States
facility: Alliance for Multispecialty Research, LLC
state: Arizona
city: Tempe
country: United States
facility: HOPE Research Institute
state: Arizona
city: Tucson
country: United States
facility: Noble Clinical Research
state: Arizona
city: Tucson
country: United States
facility: The Institute for Liver Health dba Arizona Clinical Trials
state: Arizona
city: Canoga Park
country: United States
facility: Hope Clinical Research
state: California
city: Chula Vista
country: United States
facility: eStudySite
state: California
city: Colton
country: United States
facility: Benchmark Research
state: California
city: Dublin
country: United States
facility: West Coast Research
state: California
city: Huntington Beach
country: United States
facility: Marvel Clinical Research 002, LLC
state: California
city: Huntington Beach
country: United States
facility: Marvel Clinical Research
state: California
city: Lancaster
country: United States
facility: Chemidox Clinical Trials
state: California
city: Lancaster
country: United States
facility: Chemidox Clinical Trials
state: California
city: Long Beach
country: United States
facility: Ark Clinical Research
state: California
city: Long Beach
country: United States
facility: Ark Clinical Research
state: California
city: Los Angeles
country: United States
facility: Downtown L.A. Research Center, Inc.
state: California
city: North Hollywood
country: United States
facility: Velocity Clinical Research, North Hollywood
state: California
city: Oxnard
country: United States
facility: Clinica mi Salud by Focil Med
state: California
city: Oxnard
country: United States
facility: Fomat Medical Research
state: California
city: Palmdale
country: United States
facility: De Silva Medical Inc
state: California
city: Pomona
country: United States
facility: Empire Clinical Research
state: California
city: Redding
country: United States
facility: Paradigm Clinical Research Center
state: California
city: Riverside
country: United States
facility: Artemis Institute for Clinical Research
state: California
city: Sacramento
country: United States
facility: Benchmark Research
state: California
city: San Diego
country: United States
facility: Artemis Institute for Clinical Research
state: California
city: San Diego
country: United States
facility: California Research Foundation
state: California
city: Walnut Creek
country: United States
facility: Diablo Clinical Research, Inc.
state: California
city: Aurora
country: United States
facility: Lynn Institute of Denver
state: Colorado
city: Longmont
country: United States
facility: Tekton Research LLC
state: Colorado
city: Longmont
country: United States
facility: Tekton Research, Inc.
state: Colorado
city: Milford
country: United States
facility: Clinical Research Consulting
state: Connecticut
city: Stamford
country: United States
facility: Stamford Therapeutics Consortium
state: Connecticut
city: Atlantis
country: United States
facility: JEM Research Institute
state: Florida
city: Aventura
country: United States
facility: IDEAL Clinical Research
state: Florida
city: Clearwater
country: United States
facility: Innovative Research of West Florida
state: Florida
city: Coconut Creek
country: United States
facility: Invictus Clinical Research Group, LLC
state: Florida
city: Crystal River
country: United States
facility: Nature Coast Clinical Research
state: Florida
city: Doral
country: United States
facility: Universal Axon Clinical Research, LLC (Administrative)
state: Florida
city: Hialeah
country: United States
facility: Indago Research & Health Center, Inc
state: Florida
city: Hialeah
country: United States
facility: Doral Medical Research, LLC
state: Florida
city: Lake City
country: United States
facility: Wr-Msra.Llc
state: Florida
city: Miami Lakes
country: United States
facility: Global Health Research Center, Inc.
state: Florida
city: Miami
country: United States
facility: Optimus U Corporation
state: Florida
city: Miami
country: United States
facility: Advance Medical Research Center
state: Florida
city: Miami
country: United States
facility: Optimus U Corporation
state: Florida
city: Miami
country: United States
facility: Next Phase Research Alliance
state: Florida
city: Miami
country: United States
facility: New Horizon Research Center
state: Florida
city: Miami
country: United States
facility: De La Cruz Research Center, LLC
state: Florida
city: Miami
country: United States
facility: De La Cruz Research, LLC
state: Florida
city: Miami
country: United States
facility: Clinical Site Partners LLC, dba Flourish Research
state: Florida
city: Miami
country: United States
facility: Clinical Site Partners LLC, dba Flourish Research
state: Florida
city: Miami
country: United States
facility: Clinical Site Partners, Inc dba CSP Miami
state: Florida
city: Orlando
country: United States
facility: Headlands Research Orlando
state: Florida
city: Pembroke Pines
country: United States
facility: Pines Care Research Center, LLC
state: Florida
city: Pembroke Pines
country: United States
facility: IDEAL Clinical Research
state: Florida
city: Pembroke Pines
country: United States
facility: DBC Research USA
state: Florida
city: Sarasota
country: United States
facility: Headlands Research Sarasota
state: Florida
city: Sunrise
country: United States
facility: Precision Clinical Research
state: Florida
city: Winter Park
country: United States
facility: Clinical Site Partners, Inc
state: Florida
city: Winter Park
country: United States
facility: Conquest Research, LLC
state: Florida
city: Winter Park
country: United States
facility: Conquest Research
state: Florida
city: Albany
country: United States
facility: Javara - Privia Medical Group Georgia - Albany
state: Georgia
city: Hinesville
country: United States
facility: Coastal Heritage Clinical Research
state: Georgia
city: Savannah
country: United States
facility: Javara - Privia Medical Group Georgia - Savannah
state: Georgia
city: Savannah
country: United States
facility: Javara Inc.
state: Georgia
city: Savannah
country: United States
facility: Privia Medical Group Georgia, LLC
state: Georgia
city: Savannah
country: United States
facility: Velocity Clinical Research, Savannah
state: Georgia
city: Stockbridge
country: United States
facility: Clinical Research Atlanta
state: Georgia
city: Thomasville
country: United States
facility: Javara Inc.
state: Georgia
city: Thomasville
country: United States
facility: Privia Medical Group Georgia, LLC
state: Georgia
city: Idaho Falls
country: United States
facility: Snake River Research, PLLC
state: Idaho
city: Idaho Falls
country: United States
facility: Snake River Research, PLLC
state: Idaho
city: Meridian
country: United States
facility: Solaris Clinical Research
state: Idaho
city: Chicago
country: United States
facility: Great Lakes Clinical Trials, LLC dba Flourish Research
state: Illinois
city: Chicago
country: United States
facility: Great Lakes Clinical Trials
state: Illinois
city: Melrose Park
country: United States
facility: DM Clinical Research
state: Illinois
city: Oak Brook
country: United States
facility: Affinity Health Corp
state: Illinois
city: Oak Lawn
country: United States
facility: Accellacare - DuPage
state: Illinois
city: Oak Lawn
country: United States
facility: Acellacare - DuPage
state: Illinois
city: River Forest
country: United States
facility: DM Clinical Research
state: Illinois
city: Mishawaka
country: United States
facility: MOC Research
state: Indiana
city: Valparaiso
country: United States
facility: Velocity Clinical Research Valparaiso
state: Indiana
city: Iowa City
country: United States
facility: University of Iowa Health Care
state: Iowa
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Sioux City
country: United States
facility: Meridian Clinical Research, LLC
state: Iowa
city: Sioux City
country: United States
facility: Velocity Clinical Research, Sioux City
state: Iowa
city: Lexington
country: United States
facility: Alliance for Multispecialty Research, LLC
state: Kentucky
city: Kenner
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Kenner
country: United States
facility: Ochsner Medical Center - Kenner
state: Louisiana
city: Metairie
country: United States
facility: Velocity Clinical Research, Metairie
state: Louisiana
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Rockville
country: United States
facility: Meridian Clinical Research, LLC
state: Maryland
city: Rockville
country: United States
facility: Velocity Clinical Research, Rockville
state: Maryland
city: Rockville
country: United States
facility: Velocity Clinical Research
state: Maryland
city: Beverly
country: United States
facility: ActivMed Practices & Research, LLC
state: Massachusetts
city: Methuen
country: United States
facility: ActivMed Practices & Research, LLC
state: Massachusetts
city: Worcester
country: United States
facility: University of Massachusetts Chan Medical School
state: Massachusetts
city: Farmington Hills
country: United States
facility: Michigan Center of Medical Research (MICHMER)
state: Michigan
city: Grosse Pointe Woods
country: United States
facility: Ascension St. John Hospital Vaccine Research Unit
state: Michigan
city: Troy
country: United States
facility: Oakland Medical Research
state: Michigan
city: Troy
country: United States
facility: Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
state: Michigan
city: Saint Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Saint Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Saint Louis
country: United States
facility: Sundance Clinical Research
state: Missouri
city: Elkhorn
country: United States
facility: Skyline Medical Center, PC/CCT Research
state: Nebraska
city: Omaha
country: United States
facility: Quality Clinical Research
state: Nebraska
city: Las Vegas
country: United States
facility: Wr-Crcn, Llc.
state: Nevada
city: Las Vegas
country: United States
facility: Alliance for Multispecialty Research, LLC
state: Nevada
city: North Las Vegas
country: United States
facility: Las Vegas Clinical Trials
state: Nevada
city: Portsmouth
country: United States
facility: ActivMed Practices and Research, LLC.
state: New Hampshire
city: Raritan
country: United States
facility: IMA Clinical Research
state: New Jersey
city: Somers Point
country: United States
facility: South Jersey Infectious Disease
state: New Jersey
city: Warren
country: United States
facility: IMA Clinical Research Warren
state: New Jersey
city: Binghamton
country: United States
facility: Meridian Clinical Research, LLC
state: New York
city: Binghamton
country: United States
facility: Meridian Clinical Research, LLC
state: New York
city: Bronx
country: United States
facility: CHEAR Center LLC
state: New York
city: Hartsdale
country: United States
facility: Drug Trials America
state: New York
city: Horseheads
country: United States
facility: Corning Center for Clinical Research
state: New York
city: Rochester
country: United States
facility: Rochester Clinical Research, Inc.
state: New York
city: Rochester
country: United States
facility: Rochester Clinical Research, LLC
state: New York
city: Rochester
country: United States
facility: Rochester Clinical Research, LLC
state: New York
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
city: Vestal
country: United States
facility: Velocity Clinical Research, Vestal
state: New York
city: Charlotte
country: United States
facility: Atrium Health - Strive Vaccine Research Clinic
state: North Carolina
city: Charlotte
country: United States
facility: Accellacare - Charlotte
state: North Carolina
city: Charlotte
country: United States
facility: Javara Inc.
state: North Carolina
city: Charlotte
country: United States
facility: Tryon Medical Partners, PLLC
state: North Carolina
city: Charlotte
country: United States
facility: Accellacare - Charlotte
state: North Carolina
city: Charlotte
country: United States
facility: Sensenbrenner Primary Care Research Office
state: North Carolina
city: Wilmington
country: United States
facility: Accellacare - Wilmington - 1917 Tradd Court
state: North Carolina
city: Wilmington
country: United States
facility: Accellacare - Wilmington
state: North Carolina
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
city: Cincinnati
country: United States
facility: Meridian Clinical Research, LLC
state: Ohio
city: Cincinnati
country: United States
facility: Meridian Clinical Research
state: Ohio
city: Cincinnati
country: United States
facility: Velocity Clinical Research, Mt. Auburn
state: Ohio
city: Cincinnati
country: United States
facility: Velocity Clinical Research, Mt. Auburn
state: Ohio
city: Cincinnati
country: United States
facility: Velocity Clinical Research - Cincinnati
state: Ohio
city: Cincinnati
country: United States
facility: Meridian Clinical Research, LLC
state: Ohio
city: Cincinnati
country: United States
facility: Meridian Clinical Research
state: Ohio
city: Cincinnati
country: United States
facility: Velocity Clinical Research, Springdale
state: Ohio
city: Columbus
country: United States
facility: Centricity Research Columbus Ohio Multispecialty
state: Ohio
city: Edmond
country: United States
facility: Tekton Research, Inc
state: Oklahoma
city: Edmond
country: United States
facility: Tekton Research, LLC.
state: Oklahoma
city: Yukon
country: United States
facility: Tekton Research, Inc
state: Oklahoma
city: Corvallis
country: United States
facility: The Corvallis Clinic, PC
state: Oregon
city: Grants Pass
country: United States
facility: Velocity Clinical Research, Grants Pass
state: Oregon
city: Medford
country: United States
facility: Velocity Clinical Research, Medford
state: Oregon
city: Portland
country: United States
facility: Summit Headlands, LLC
state: Oregon
city: Portland
country: United States
facility: Kaiser Permanente Northwest-Center for Health Research
state: Oregon
city: Camp Hill
country: United States
facility: Capital Area Research, LLC
state: Pennsylvania
city: Erie
country: United States
facility: Central Erie Primary Care
state: Pennsylvania
city: Mechanicsburg
country: United States
facility: West Shore Family Practice, P. C.
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Philadelphia
country: United States
facility: Penn Prevention Unit
state: Pennsylvania
city: East Greenwich
country: United States
facility: Velocity Clinical Research, Providence
state: Rhode Island
city: Knoxville
country: United States
facility: Alliance for Multispecialty Research, LLC
state: Tennessee
city: Knoxville
country: United States
facility: Accellacare US Inc., d/b/a Accellacare of Knoxville
state: Tennessee
city: Nashville
country: United States
facility: Clinical Research Associates, Inc.
state: Tennessee
city: Austin
country: United States
facility: Benchmark Research
state: Texas
city: Austin
country: United States
facility: Innovo Research - Austin Regional Clinic
state: Texas
city: Austin
country: United States
facility: Tekton Research, LLC.
state: Texas
city: Beaumont
country: United States
facility: Tekton Research, Inc.
state: Texas
city: Beaumont
country: United States
facility: Tekton Research, LLC.
state: Texas
city: Conroe
country: United States
facility: Javara Inc.
state: Texas
city: Conroe
country: United States
facility: Privia Medical Group Gulf Coast, PLLC
state: Texas
city: Dallas
country: United States
facility: North Texas Infectious Diseases Consultants, P.A
state: Texas
city: Fort Worth
country: United States
facility: Benchmark Research
state: Texas
city: Fort Worth
country: United States
facility: Benchmark Research
state: Texas
city: Fort Worth
country: United States
facility: Texas Health Family Care
state: Texas
city: Fort Worth
country: United States
facility: Benchmark Research
state: Texas
city: Friendswood
country: United States
facility: Allure Health at Mt. Olympus Medical Research
state: Texas
city: Houston
country: United States
facility: Hany H. Ahmed, MD
state: Texas
city: Houston
country: United States
facility: Helios Clinical Research - HOU
state: Texas
city: Houston
country: United States
facility: HG Pediatrics
state: Texas
city: Houston
country: United States
facility: Trio Clinical Trials, LLC
state: Texas
city: Houston
country: United States
facility: Van Tran Family Practice
state: Texas
city: Houston
country: United States
facility: Ventavia Research Group, LLC
state: Texas
city: Houston
country: United States
facility: Centex Studies
state: Texas
city: Houston
country: United States
facility: DM Clinical Research - Cy Fair
state: Texas
city: Houston
country: United States
facility: DM Clinical Research ? CyFair
state: Texas
city: Houston
country: United States
facility: DM Clinical Research - Bellaire
state: Texas
city: Houston
country: United States
facility: DM Clinical Research - Bellaire
state: Texas
city: Houston
country: United States
facility: Texas Center for Drug Development, Inc.
state: Texas
city: Houston
country: United States
facility: Centex Studies
state: Texas
city: Humble
country: United States
facility: DM Clinical Research - Humble
state: Texas
city: Humble
country: United States
facility: DM Clinical Research - Humble
state: Texas
city: Humble
country: United States
facility: DM Clinical Research - MDC
state: Texas
city: Laredo
country: United States
facility: Milton Haber, M.D.
state: Texas
city: Laredo
country: United States
facility: Milton Haber, MD
state: Texas
city: Mesquite
country: United States
facility: SMS Clinical Research
state: Texas
city: Mesquite
country: United States
facility: SMS Clinical Research
state: Texas
city: San Antonio
country: United States
facility: Sun Research Institute
state: Texas
city: San Antonio
country: United States
facility: Clinical Trials of Texas, LLC dba Flourish Research
state: Texas
city: San Antonio
country: United States
facility: Clinical Trials of Texas, LLC
state: Texas
city: San Antonio
country: United States
facility: Clinical Trials of Texas, LLC
state: Texas
city: Sugar Land
country: United States
facility: Dynamed Clinical Research, LP d/b/a DM Clinical Research
state: Texas
city: Sugar Land
country: United States
facility: Dynamed Clinical Research, LP d/b/a DM Clinical Research
state: Texas
city: Sugar Land
country: United States
facility: Javara Inc.
state: Texas
city: Sugar Land
country: United States
facility: Privia Medical Group Gulf Coast, PLLC
state: Texas
city: Sugar Land
country: United States
facility: Mt Olympus Medical Research
state: Texas
city: Tomball
country: United States
facility: DM Clinical Research, Martin Diagnostic Clinic
state: Texas
city: Tomball
country: United States
facility: Martin Diagnostic Clinic
state: Texas
city: Draper
country: United States
facility: J. Lewis Research Inc. / Foothill Family Clinic Draper
state: Utah
city: Draper
country: United States
facility: J. Lewis Research, Inc. / Foothill Family Clinic Draper
state: Utah
city: Layton
country: United States
facility: Tanner Clinic
state: Utah
city: South Jordan
country: United States
facility: J. Lewis Research, Inc. / Jordan River Family Medicine
state: Utah
city: West Jordan
country: United States
facility: Velocity Clinical Research, Salt Lake City
state: Utah
city: Suffolk
country: United States
facility: Centricity Research Suffolk Primary Care
state: Virginia
city: Suffolk
country: United States
facility: Suffolk Multispecialty Research
state: Virginia
city: Suffolk
country: United States
facility: Virginia Gastroenterology Clinical Research
state: Virginia
city: Bellevue
country: United States
facility: Northwest Clinical Research Center
state: Washington
city: Port Orchard
country: United States
facility: Sound Medical Research
state: Washington
city: Tacoma
country: United States
facility: MultiCare Institute for Research & Innovation
state: Washington
city: Tacoma
country: United States
facility: MultiCare Medical Group
state: Washington
city: Wenatchee
country: United States
facility: Central Washington Health Services Association d/b/a Confluence Health
state: Washington
city: Wenatchee
country: United States
facility: Research Building
state: Washington
city: Wenatchee
country: United States
facility: Wenatchee Valley Hospital
state: Washington
city: Wauwatosa
country: United States
facility: Allegiance Research Specialists, LLC
state: Wisconsin
city: Caba
country: Argentina
facility: Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
state: Buenos Aires
city: Caba
country: Argentina
facility: Fundación Respirar
state: Buenos Aires
city: La Plata
country: Argentina
facility: Clinica Privada Instituto Medico Platense S.A.
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Instituto De Investigaciones Clínicas Mar Del Plata
state: Buenos Aires
city: San Miguel de Tucuman
country: Argentina
facility: Clinica Mayo de Urgencias Medicas Cruz Blanca S.R.L
state: Tucuman
city: San Miguel de Tucuman
country: Argentina
facility: Hospital de Clinicas Presidente Nicolas Avellaneda
state: Tucuman
city: Cordoba
country: Argentina
facility: Clinica Privada del Sol S.A.
city: Salta
country: Argentina
facility: IMAC - Instituto Medico de Alta Complejidad
city: Edmonton
country: Canada
facility: Kaye Edmonton Clinic
state: Alberta
city: Edmonton
country: Canada
facility: Stollery Children's Hospital
state: Alberta
city: Edmonton
country: Canada
facility: University Of Alberta Hospital
state: Alberta
city: Brampton
country: Canada
facility: Aggarwal and Associates Limited
state: Ontario
city: Guelph
country: Canada
facility: Dawson Clinical Research Inc.
state: Ontario
city: Guelph
country: Canada
facility: Dawson Clinical Research Inc
state: Ontario
city: Hamilton
country: Canada
facility: Premier Clinical Trial Network
state: Ontario
city: Hamilton
country: Canada
facility: Hamilton Medical Research Group
state: Ontario
city: Toronto
country: Canada
facility: Centricity Research Toronto LMC Multispecialty
state: Ontario
city: Toronto
country: Canada
facility: LMC Clinical Research Inc. (Clinical Pharmacology Unit)
state: Ontario
city: Toronto
country: Canada
facility: Dr. Anil K. Gupta Medicine Professional Corporation
state: Ontario
city: Toronto
country: Canada
facility: Centricity Research Toronto Manna Multispecialty
state: Ontario
city: Toronto
country: Canada
facility: Manna Research (Toronto)
state: Ontario
city: Joliette
country: Canada
facility: Diex Recherche Joliette Inc
state: Quebec
city: Mirabel
country: Canada
facility: Centricity Research Mirabel Multispecialty
state: Quebec
city: Montreal
country: Canada
facility: Clinique de Médecine Urbaine du Quartier Latin
state: Quebec
city: Québec
country: Canada
facility: Alpha Recherche Clinique
state: Quebec
city: Sherbrooke
country: Canada
facility: Diex Recherche Sherbrooke Inc.
state: Quebec
city: St-Charles-Borromee
country: Canada
facility: Diex Recherche Joliette Inc.
state: Quebec
city: Victoriaville
country: Canada
facility: Diex Recherche Victoriaville Inc.
state: Quebec
city: Victoriaville
country: Canada
facility: Diex Recherche Victoriaville Inc.
state: Quebec
city: Victoriaville
country: Canada
facility: Diex Recherche Victoriaville Inc.
state: Quebec
city: Quebec
country: Canada
facility: Diex Recherche Quebec Inc.
city: Quebec
country: Canada
facility: Centre de Recherche Saint-Louis
city: Quebec
country: Canada
facility: Diex Recherche Joliette Inc
city: Espoo
country: Finland
facility: Espoo Vaccine Research Clinic
city: Helsinki
country: Finland
facility: FVR, Etelä-Helsingin rokotetutkimusklinikka
city: Helsinki
country: Finland
facility: Helsinki East Vaccine Research Clinic
city: Jyväskylä
country: Finland
facility: Terveystalo Jyväskylä
city: Järvenpää
country: Finland
facility: Järvenpää Vaccine Research Clinic
city: Kokkola
country: Finland
facility: Kokkola Vaccine Research Clinic
city: Oulu
country: Finland
facility: Oulu Vaccine Research Clinic
city: Pori
country: Finland
facility: Pori Vaccine Research Clinic
city: Seinajoki
country: Finland
facility: Seinäjoki Vaccine Research Clinic
city: Tampere
country: Finland
facility: Tampere Vaccine Research Clinic
city: Tampere
country: Finland
facility: Terveystalo Tampere
city: Turku
country: Finland
facility: Terveystalo Turku Pulssi
city: Turku
country: Finland
facility: Turku Vaccine Research Clinic
city: Fukuoka-shi
country: Japan
facility: Tenjin General Clinic
state: Fukuoka
city: Itoshima
country: Japan
facility: Seishinkai Inoue Hospital
state: Fukuoka
city: Amagasaki
country: Japan
facility: Sasaki Clinic
state: Hyōgo
city: Yokohama
country: Japan
facility: Motomachi Takatsuka Naika Clinic
state: Kanagawa
city: Osaka-shi
country: Japan
facility: Medical Corporation Heishinkai OPHAC Hospital
state: Osaka
city: Kawaguchi
country: Japan
facility: Sugiura Clinic
state: Saitama
city: Chuo-ku
country: Japan
facility: Nihonbashi Sakura Clinic
state: Tokyo
city: Chuo-ku
country: Japan
facility: Tokyo Eki Center Building Clinic
state: Tokyo
city: Chuo-ku
country: Japan
facility: Fukuwa Clinic
state: Tokyo
city: Chuo-ku
country: Japan
facility: Tokyo Asbo Clinic
state: Tokyo
city: Hachioji-shi
country: Japan
facility: Medical Corp. Seikoukai New Medical Research System Clinic
state: Tokyo
city: Shibuya-ku
country: Japan
facility: Hillside Clinic Jingumae
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Clinical Research Hospital Tokyo
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Clinical Research Hospital Tokyo
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Oda Clinic
state: Tokyo
city: Sumida-ku
country: Japan
facility: Souseikai Sumida Hospital
state: Tokyo
city: Toshima-ku
country: Japan
facility: Sekino Hospital
state: Tokyo
city: Fukuoka
country: Japan
facility: SOUSEIKAI PS Clinic
city: Osaka
country: Japan
facility: AMC Nishiumeda Clinic
city: Amersfoort
country: Netherlands
facility: Meander Medisch Centrum
city: Amsterdam
country: Netherlands
facility: PoliDirect Amsterdam West
city: Eindhoven
country: Netherlands
facility: Huisartsencentrum Parklaan
city: Groningen
country: Netherlands
facility: Huisartsenpraktijk Radesingel
city: Helmond
country: Netherlands
facility: Gezondheidscentrum Leonardus
city: Hoofddorp
country: Netherlands
facility: Spaarne Gasthuis
city: Nieuwegein
country: Netherlands
facility: PoliDirect Nieuwegein
city: Rotterdam
country: Netherlands
facility: Franciscus Gasthuis & Vlietland, location Gasthuis
city: Soest
country: Netherlands
facility: Huisartsen Soest
city: Utrecht
country: Netherlands
facility: UMC Utrecht
city: Zeist
country: Netherlands
facility: Julius Clinical Breda
city: Bloemfontein
country: South Africa
facility: Josha Research
state: FREE State
city: Welkom
country: South Africa
facility: Welkom Clinical Trial Centre (MERC WELKOM)
state: FREE State
city: Benoni
country: South Africa
facility: Worthwhile Clinical Trials
state: Gauteng
city: Kempton Park
country: South Africa
facility: MERC Research (Pty) Ltd - Kempton
state: Gauteng
city: Kempton Park
country: South Africa
facility: MERCLINCO (Pty) Ltd - Kempton
state: Gauteng
city: Midrand
country: South Africa
facility: Dr A Jacovides & Partners Inc.
state: Gauteng
city: Newtown
country: South Africa
facility: Newtown Clinical Research Centre (PTY) LTD
state: Gauteng
city: Pretoria
country: South Africa
facility: Emmed Research
state: Gauteng
city: Pretoria
country: South Africa
facility: Global Clinical Trials
state: Gauteng
city: Pretoria
country: South Africa
facility: About Allergy
state: Gauteng
city: Pretoria
country: South Africa
facility: Into Research
state: Gauteng
city: Pretoria
country: South Africa
facility: Jongaie Research
state: Gauteng
city: Pretoria
country: South Africa
facility: Synexus SA- Watermeyer Clinical Research Center
state: Gauteng
city: Soshanguve
country: South Africa
facility: Setshaba Research Centre
state: Gauteng
city: Soweto
country: South Africa
facility: Wits Vaccines & Infectious Diseases Analytics
state: Gauteng
city: Vereeniging
country: South Africa
facility: FCRN Clinical Trial Centre
state: Gauteng
city: Middelburg
country: South Africa
facility: MERC Research (Pty) Ltd - Middelburg
state: Mpumalanga
city: Cape Town
country: South Africa
facility: Synexus - Helderberg Clinical Research Centre - Somerset West
state: Western CAPE
city: Cape Town
country: South Africa
facility: TREAD Research
state: Western CAPE
city: Paarl
country: South Africa
facility: Be Part Yoluntu Centre
state: Western CAPE
city: Somerset West
country: South Africa
facility: Helderberg Clinical Trials Centre
state: Western CAPE
city: Pretoria
country: South Africa
facility: Emmed Research
city: Pretoria
country: South Africa
facility: Botho Ke Bontle Health Services
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: